Key Points
- CEO Nello Mainolfi sold 30,000 shares on Dec. 31 at an average price of $78.06 for $2,341,800, trimming his stake by 4.33% to 663,077 shares valued at about $51.76 million.
- The Dec. 31 sale follows multiple recent insider disposals — 100,000 shares on Dec. 8 at $89.17 and 30,000 shares on Oct. 29 at $60.99 — showing a pattern of sizable share sales by the CEO.
- Kymera (KYMR) trades around $77.81 with a $5.6B market cap and recent negative earnings/revenue misses, yet analysts hold a consensus “Buy” rating and an average price target of $116.30 after several upgrades.
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $78.06, for a total value of $2,341,800.00. Following the completion of the sale, the chief executive officer owned 663,077 shares in the company, valued at $51,759,790.62. This trade represents a 4.33% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Nello Mainolfi also recently made the following trade(s):
- On Monday, December 8th, Nello Mainolfi sold 100,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.17, for a total value of $8,917,000.00.
- On Wednesday, October 29th, Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $60.99, for a total value of $1,829,700.00.
Kymera Therapeutics Trading Down 0.4%
Shares of KYMR opened at $77.81 on Thursday. Kymera Therapeutics, Inc. has a 12-month low of $19.44 and a 12-month high of $103.00. The company has a market cap of $5.60 billion, a PE ratio of -21.67 and a beta of 2.28. The stock has a 50-day moving average price of $70.91 and a 200-day moving average price of $55.61.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.19). The company had revenue of $2.76 million during the quarter, compared to the consensus estimate of $23.15 million. Kymera Therapeutics had a negative return on equity of 32.92% and a negative net margin of 674.81%. As a group, analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on KYMR shares. B. Riley lifted their price objective on shares of Kymera Therapeutics from $80.00 to $117.00 and gave the stock a "buy" rating in a report on Monday, December 22nd. UBS Group upgraded Kymera Therapeutics to a "strong-buy" rating in a research report on Thursday, December 4th. Truist Financial lifted their price target on Kymera Therapeutics from $80.00 to $116.00 and gave the stock a "buy" rating in a research note on Tuesday, December 9th. BTIG Research set a $138.00 price objective on Kymera Therapeutics in a report on Monday, December 8th. Finally, Wall Street Zen upgraded Kymera Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, November 8th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Kymera Therapeutics has an average rating of "Buy" and a consensus target price of $116.30.
Get Our Latest Stock Analysis on KYMR
Institutional Investors Weigh In On Kymera Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KYMR. Farther Finance Advisors LLC grew its holdings in Kymera Therapeutics by 642.9% in the 2nd quarter. Farther Finance Advisors LLC now owns 624 shares of the company's stock worth $27,000 after acquiring an additional 540 shares during the last quarter. Larson Financial Group LLC boosted its holdings in shares of Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company's stock worth $44,000 after purchasing an additional 349 shares during the period. PNC Financial Services Group Inc. grew its stake in shares of Kymera Therapeutics by 506.6% in the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company's stock worth $40,000 after purchasing an additional 770 shares during the last quarter. Bessemer Group Inc. increased its holdings in Kymera Therapeutics by 652.0% during the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company's stock valued at $53,000 after purchasing an additional 815 shares during the period. Finally, Osaic Holdings Inc. increased its holdings in Kymera Therapeutics by 18,050.0% during the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company's stock valued at $48,000 after purchasing an additional 1,083 shares during the period.
About Kymera Therapeutics
(
Get Free Report)
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company's pipeline emphasizes immunology and oncology.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
